Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Has Consensus Target Price of $106.06

Posted by Stanley Muller on Oct 21st, 2026

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $105.44.

A number of equities analysts have recently commented on the stock. Morgan Stanley upgraded shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research note on Tuesday, September 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Thursday, October 15th. Barclays upped their target price on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a report on Monday. Finally, Citizens Jmp increased their price target on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th.

Get Our Latest Stock Analysis on Cytokinetics

Insider Transactions at Cytokinetics

In other news, Director B. Parshall sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the sale, the director directly owned 10,784 shares of the company’s stock, valued at approximately $770,840.32. This represents a 31.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 97,926 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the completion of the sale, the chief executive officer owned 385,320 shares of the company’s stock, valued at $26,714,235.60. This trade represents a 20.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,426 shares of company stock worth $13,543,855 in the last ninety days. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently added to or reduced their stakes in CYTK. V Square Quantitative Management LLC increased its position in shares of Cytokinetics by 71.5% in the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 191 shares during the period. GAMMA Investing LLC grew its stake in Cytokinetics by 8.6% during the third quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 213 shares in the last quarter. Strs Ohio increased its holdings in Cytokinetics by 2.4% in the 1st quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 300 shares during the period. AlphaCentric Advisors LLC increased its holdings in Cytokinetics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 305 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in shares of Cytokinetics by 2.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 13,050 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 345 shares in the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III). The approval expands Cytokinetics’ international commercial opportunity and reinforces confidence in the drug’s regulatory and clinical profile. Health Canada approval announcement
Positive Sentiment: Coverage highlighted growing MYQORZO prescriptions, international launches and encouraging clinical data, suggesting the product could become an increasingly important growth driver for Cytokinetics. MYQORZO growth analysis
Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $140 price target, implying substantial upside from recent trading levels and providing a bullish counterpoint to more cautious views. HC Wainwright rating report
Neutral Sentiment: Cytokinetics granted options covering 60,465 shares and 40,084 restricted stock units to 29 recently hired employees as inducements. The grants support recruitment but may create modest future share dilution. Inducement grants announcement
Negative Sentiment: BofA Securities lowered its price target to $81 from $85 while maintaining a Neutral rating, signaling less near-term conviction despite the target remaining above the recent share price. BofA price-target update
Negative Sentiment: Wall Street Zen downgraded CYTK to Sell, adding to investor concerns about valuation, execution and the company’s continuing losses. Wall Street Zen rating downgrade
Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares worth approximately $224,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but still represents a modest insider-selling overhang. SEC insider transaction filing

Cytokinetics Stock Up 2.1%

Shares of CYTK stock opened at $63.95 on Wednesday. Cytokinetics has a 12 month low of $54.30 and a 12 month high of $88.31. The company’s fifty day simple moving average is $69.63 and its 200-day simple moving average is $73.23. The firm has a market cap of $7.96 billion, a PE ratio of -8.86 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. During the same period last year, the business posted ($1.12) EPS. The firm’s revenue for the quarter was down 57.1% on a year-over-year basis. On average, equities analysts predict that Cytokinetics will post -5.98 earnings per share for the current fiscal year.

About Cytokinetics

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.